2015年1月7日讯/生物谷BIOON/--近日安进预付6000万美元，将与Kite Pharma展开合作，用于研发新的肿瘤免疫疗法。

此番安进与Kite Pharma的战略联盟将会促进嵌合抗原受体CAR-T细胞免疫疗法的研发和商品化，安进的肿瘤靶标和Kite的工程化自体细胞治疗平台可以借助此次合作的得以深度整合。

在本次合作中，Kite将会提供研发和制造的能力和技术，并且将会承担所有临床前研究和细胞生产（加工）的工作。目前，两家公司都在承担各自临床研发和CAR-T免疫候选疗法商业化的职能。

在资金方面，Kite获得了安进6000万美元的预付款，以及临床研究许可申请过程中的研发费用，并且在安进的每个项目中都有资格获得高达5.25亿美元的进度付款，加上销售额的一直两位数的分层提成，以及CAR-T细胞的知识产权。安进将在Kite的每个项目中获得5.25亿美元的进度付款，加上销售额的一位数的分层提成。进一步的条款尚未披露。

Kite的董事长Arie Belldegrun表示，此番两家公司的合作将会极大地促进CAR-T免疫疗法，使其真正成为一种强效的肿瘤治疗方式。

目前CAR/TCR领域形成了KITE/安进、辉瑞/Cellectis、新基/Blue、以及Immunocore/Adaptimmune/Genentech/GSK/阿斯利康/礼来超级联盟等几大阵营，而新贵Juno仍在单枪作战，新一轮的腥风血雨大战即将登陆癌症免疫疗法领域，让我们拭目以待。(生物谷Bioon.com）

相关阅读：CART：治愈癌症的终极疗法？

原文 Amgen， Kite Pharma hook up in cancer immunotherapy pact

Amgen is sinking $60 million upfront into a research and licensing deal to develop new immunotherapies for cancer.

The strategic alliance will see the groups develop and commercialise new Chimeric Antigen Receptor (CAR) T cell immunotherapies by combining Amgen’s cancer targets with Kite\'s engineered autologous cell therapy (eACT) platform.

Under the deal， Kite is also to provide research and development/manufacturing capabilities and expertise， and will carry out all preclinical research and cell manufacturing/processing through Investigational New Drug (IND) filing. At this point， each company takes on responsibility for clinical development and commercialisation of their respective CAR therapeutic candidates.

On the financial side， Kite gets the upfront $60 million from Amgen as well as cash for R D costs through IND filing， and it is also eligible for up to $525 million in milestone payments per Amgen programme， plus tiered high single- to double-digit royalties for sales and the license of its intellectual property for CAR T cell products. Amgen stands to gain up to $525 million in milestone payments per Kite program， plus tiered single-digit sales royalties. Further terms were not disclosed.

“We believe that the therapeutic candidates resulting from the collaboration will have the potential to dramatically transform CAR approaches and to become some of the most powerful therapies for the treatment of cancer，” said Kite’s chief executive Arie Belldegrun， commenting on the partnership’s potential.